In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

Tolerability Benefits For Infused Form

 
• By Sushmita Panda
  
Multiple Myeloma
Potential New Multiple Myeloma Option Moves Into Phase IIa (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Therapy Areas